Nitric oxide may play a role in phosphodiesterase (PDE) inhibitor-induced rat mesenteric vasculitis. The present study was conducted to identify cellular sources of iNOS, determine the distribution of nitrotyrosine (NT) residues as a footprint of peroxynitrite (ONOO − ) production, and evaluate their association with vascular apoptosis. To dissociate primary events from secondary changes associated with the inflammatory response, rats were given the PDE IV inhibitor CI-1018 orally at 750 mg/kg alone or concurrently with dexamethasone (DEX) intraperitoneally at 1 mg/kg for 4-5 days. Neutrophil (PMN) involvement in apoptosis was investigated in CI-1018 treated rats dosed with rabbit anti-rat PMN serum (APS). iNOS expression, NT residues, and caspase-3 were detected by immuno-histochemistry. Apoptosis was evaluated by TUNEL assay. CI-1018 induced vascular lesions were associated with iNOS expression in endothelial cells and inflammatory infiltrates; NT was evident only in the latter. Caspase-3 and TUNEL-positive staining were prominent only in medial smooth muscle cells (SMC) from CI-1018-treated rats and only when associated with active inflammation. iNOS-and NT-positive inflammatory cells were present in close proximity to SMC with caspase-3 staining. Inflammatory infiltrates were absent in rats given DEX with minimal SMC necrosis and hemorrhage remained. DEX eliminated apoptosis and immunoreactivity associated with caspase-3, iNOS, and NT. APS depletion of PMNs decreased the incidence and severity of vasculitis but failed to abolish completely caspase-3 immunoreactivity. Expression patterns for caspase-3, iNOS, and NT demonstrated that nitrative stress is a prominent feature of PDE inhibitor-induced vasculitis, with a possible role in medial SMC apoptosis. Further, medial SMC apoptosis may not be a primary event, but instead may be secondary to the inflammatory response.
INTRODUCTION
Development of PDE IV inhibitors as therapeutic agents has focused primarily on potential anti-asthmatic effects, but additional consideration has been given to treatment of other inflammatory diseases, such as rheumatoid arthritis, atopic dermatitis, and inflammatory bowel disease (11, 12, 34) . Clinical investigation of PDE inhibitors has been hindered, however, by their association with an insidious vascular toxicity in nonclinical animal models. For example, suprapharmacologic doses of PDE III and PDE IV inhibitors have been found to induce lesions in splanchnic arteries in rats (17, 18, 21) . Histopathologically, mesenteric vasculitis induced by PDE inhibitors is characterized by medial necrosis and hemorrhage with perivascular edema and mixed inflammatory cell infiltration. The pathogenesis of vasculitis induced by PDE inhibitors is currently poorly understood. Recent studies have demonstrated that mesenteric vasculitis in rats induced by a PDE type III inhibitor is associated with apoptosis of vascular endothelial and smooth muscle cells (37) .
Apoptosis has not been extensively evaluated in rats given PDE IV inhibitors, however, and mediators of apoptotic signaling have not been fully described. Inducible nitric oxide synthase (iNOS), a high output isoform of nitric oxide synthase, has been shown to mediate tissue injury, inflammation and apoptosis (20, (25) (26) (27) . Excess production of nitric oxide radical (NO . ) and upregulation of Fas expression has been associated with apoptotic cell death in vascular smooth muscle cells (7, 15) . The present study was conducted to identify possible relevant cellular sources of iNOS, to characterize the distribution of nitrotyrosine (NT) residues as a footprint of peroxynitrite (ONOO − ) production, and to evaluate their association with apoptosis induced by the PDE IV inhibitor CI-1018. A secondary objective was to clarify if the apoptotic or nitrative stress events are associated with the inflammatory process or instead are manifestations of PDE IV inhibition.
MATERIALS AND METHODS
Animals: Random bred, female albino Wistar rats (Crl:WI)BR were purchased from Charles River Laboratory (Raleigh, NC). Before being placed on the study, animals were acclimated for 7 days in individual stainless steel wire mesh cages in temperature (21 • C-26
• C) and humidity (30%-70% RH) controlled rooms with a 12-hour light cycle. Animals were fed (Lab Diet Certified Rodent Chow-5002) with water provided ad libitum. This study was conducted in accordance with the current guidelines for animal welfare (Guide for the Care and Use of Laboratory Animals, 1996). The procedures used in this study have been reviewed and approved by the Institutional Animal Care and Use Committee.
Compounds and Compound Administration: CI-1018, (+)-N-[3,4,6,7-tetrahydro-9-methyl-4-oxo-1-phenylpyrrolo-[3,2,1-jk] [1, 4] benzodiazepin-3-yl]-4-pyridinecarboxamide, is an orally active selective inhibitor of type IV phosphodiesterase (PDE-IV), previously in development as an anti-asthmatic compound. Daily oral gavage doses of CI-1018 were administered as suspensions in 1% 639 methylcellulose/5% polyethylene glycol (PEG) 400 at a dose volume of 10 mL/kg as described later. When appropriate to experimental design, dexamethasone (Sigma, St Louis, MO) was dissolved in saline and administered intraperitoneally in a dose volume of 1 mL/kg and rabbit anti-rat PMN antiserum (Accurate Chemical and Scientific Corporation, Westbury, NY) was given by intraperitoneal injection undiluted at 2 mL/kg.
Experimental Procedures: The first study was designed to identify cellular sources of iNOS, determine the distribution of NT residues and evaluate potential association with vascular apoptosis in CI-1018-treated rats. To investigate if apoptotic or nitrative stress events are associated with the inflammatory process or instead are manifestations of PDE IV inhibition, dexamethasone, a glucocorticoid antiinflammatory agent was used. Twenty-four female Wistar rats were assigned randomly to 4 groups of 6 rats each. Twenty-four hours prior to initiation of dosing with CI-1018 and daily thereafter, rats in Groups 2 and 4 received daily intraperitoneal injections of 1 mg/kg dexamethasone for 5 consecutive days. Rats in Groups 1 and 3 received intraperitoneal injections of saline vehicle. Groups 3 and 4 received daily oral doses of 750 mg/kg CI-1018 for 4 consecutive days. A robust vasculitic response to CI-1018 was previously demonstrated under these experimental conditions (4, 32) . Groups 1 and 2 received daily oral doses of vehicle used to deliver CI-1018. Treatment groups and doses are presented in Table 1 .
In the second study, designed to investigate a potential role for neutrophils in CI-1018-induced apoptosis, rabbit anti-rat PMN antiserum (APS) was used to deplete circulating blood neutrophils. Twenty-four female Wistar rats were assigned randomly to 4 groups of 6 rats each. Animals in groups 6 and 8 received 2 mL/kg intraperitoneal injections of APS 12 hours prior to and 48 hours after the first dose of CI-1018 or the appropriate vehicle. This dosing regimen of APS was shown in a separate experiment to be effective in significantly decreasing circulating blood neutrophil counts. Rats in groups 5 and 7 received intraperitoneal injections of pooled sterile normal rabbit serum. Groups 7 and 8 received 3 daily oral doses of CI-1018 at 750 mg/kg commencing 12 hours after the first dose of APS. Groups 5 and 6 received oral doses of vehicle used to deliver CI-1018. Blood samples for leukocyte counts and differentials were collected from the jugular vein of anesthetized rats prior to and 12, 36, and 60 hours after the first dose of APS or control serum and by cardiocentesis at termination. All animals were euthanized by CO 2 asphyxiation and necropsied 24 hours after the last dose of CI-1018. Treatment groups and doses are presented in Table 1 .
Pathology:
Vasculature from the mesoduodenum (including pancreas), mesojejunum and mesoileum (including lymph node) were affixed with staples to wax mounting strips and fixed in 10% buffered formalin for 24 hours. Three representative samples of vascular tissue from each region were embedded in paraffin, sectioned at a thickness of 3 µm and stained with hematoxylin and eosin for histopathological evaluation. Arterial necrosis and inflammation were graded by a single observer using semiquantitative criteria based upon the percentage of medial area affected by hemorrhage and necrosis (1, 17, 31) as follows: Minimal = <10% of medial area Mild = 10-50% of medial area Moderate = 50-90% of medial area Marked = 90-100% of medial area
Immunohistochemistry: Immunohistochemical staining of tissues for detection of iNOS, NT, and the cleaved form of caspase-3 was performed by using Ventana Discovery autostainer system (Ventana Medical Inc, Tucson, AZ). Briefly, slides were deparaffinized by EZ prep buffer (Ventana Medical Inc.) followed by antigen retrieval for 20 minutes at 100
• C using Tris/Borate/EDTA cell conditioning solution CC1 (Ventana Medical Inc). Endogenous peroxidase was inactivated using an enhanced inhibitor provided in the staining kit and nonspecific antibody binding was blocked by applying 3% blocking solution (Roche) for 30 minutes. Primary antibodies (Table 2 ) were manually applied, separately, for 30 minutes followed by incubation with the endogenous biotin blocker provided in the kit (Ventana Medical Inc). The slides were then incubated with biotinylated goat anti-rabbit IgG or horse anti-mouse IgG (Vector) for 30 minutes followed by avidin-biotin-immunocomplex (ABC). Visualization was facilitated by enhanced diaminobenzidine (DAB) or alkaline phosphatase-based red chromagen (AP-RED) (Ventana Medical Inc). Slides were then counterstained with hematoxylin.
Double Labeling of Caspase-3 with iNOS, Capase-3 with Nitrotyrosine and Caspase-3 with Smooth Muscle Actin:
All dual immunohistochemistry stains were performed with the Ventana Discovery autostainer system. An enhanced DAB detection procedure was performed as described earlier and was followed by enhanced AP-RED and hematoxylin counterstaining. An enhanced DAB detection procedure was performed for caspase-3 followed by enhanced AP-RED detection for smooth muscle actin, iNOS or nitrotyrosine. TUNEL Analysis: In situ detection of DNA fragments was performed using a TACS TdT Labeling Kit (Trevigen, Gaithersburg, MD). Briefly, slides were deparaffinized, digested with 20 µg/ml proteinase K for 15 minutes at 37
• C, and washed with deionized water. Endogenous peroxidase activity was blocked with 3% hydrogen peroxide for 5 minutes. After washing, slides were incubated in mixture of TdT, Mn 2+ ions, and TdT dNTP for 1 hour at 37
• C. The reaction was stopped with TdT Stop Buffer for 5 minutes. After washing with deionized water, the slides were incubated with Streptavidin-HRP (diluted 1:500) solution for 10 minutes at RT. The positive reaction was detected using TACS-Blue Label solution. Slides were counterstained with Nuclear Fast Red for 5 minutes, dehydrated in ethanol, cleared in o-xylene, and mounted.
Neutrophil (PMN) Counts: Total and differential cell counts were made with the Cell-Dyn 3500 system (Abbott Laboratories, Abbott Park, IL) to determine the number and percentage of PMNs.
RESULTS

Histopathology:
No mesenteric vascular lesions were noted in vehicle controls ( Figure 1A ) or in animals given dexamethasone alone. All 6 animals treated with CI-1018 alone, designated in Table 1 as group 3, had evidence of mesenteric vascular injury characterized by subacute mild to marked multifocal inflammation of medium and small arteries. Vasculitis in this group consisted of medial necrosis and hemorrhage with mixed inflammatory cell infiltrates in the media and adventitia ( Figure 1B) . Hemorrhage/fibrin, edema and granulation tissue were noted in the adventitia and perivascular tissue. Plump basophilic reactive endothelial cells were also observed in affected arteries. In contrast to rats given CI-1018 alone, rats dosed with both dexamethasone and CI-1018, designated in Table 1 as group 4, exhibited minimal mesenteric vascular lesions characterized by multifocal minimal medial necrosis and degeneration with vacuolation of medial smooth muscle cells. A few red blood cells were noticed in the media ( Figure 1C ). Concomitant inflammation was not associated with vascular injury in these animals hence the diagnosis of vasculitis was discounted in favor of the more appropriate descriptor "arteriopathy." Dominant histopathological findings in rats treated with CI-1018 with and without dexamethasone are summarized in Table 3 . Mesenteric vascular lesions were not observed in animals given APS (group 5) or normal rabbit serum alone (group 6). Mild to marked mesenteric vasculitis with histopathologic changes similar to those described above were noted in four animals given CI-1018 and normal rabbit serum concurrently (group 7). Neutrophil depletion by APS decreased the incidence and severity of vasculitis induced by CI-1018 (group 8), but minimal mesenteric arteriopathy, characterized by necrosis and degeneration of smooth muscle cells with hemorrhage remained a predominant histopathological feature of this group ( Figure 1D ). Arteriopathy was associated with no to minimal mononuclear cell infiltration. Two animals treated concurrently with CI-1018 and APS had mild mesenteric vasculitis characterized by edema, hemorrhage, medial necrosis, and degeneration, with minimal to moderate inflammatory cell infiltrates that was predominantly mononuclear in nature. Dominant histopathological findings from this study are summarized in Table 4 .
Immunohistochemical Localization of iNOS and Nitrotyrosine: Immunohistochemical staining of histological sections from mesenteric vessels revealed no iNOS expression or NT immunoreactivity in control groups (Figures 2A and 3A) . TOXICOLOGIC PATHOLOGY In contrast, samples from CI-1018-treated rats with concomitant inflammation showed intense iNOS immunoreactivity in the endothelium as well as in medial and perivascular inflammatory cell infiltrates ( Figure 2B, C) . Similarly, significant immunoreactivity against NT residues was noted in inflammatory cell infiltrates ( Figure 3B , C) in only CI-1018 treated animals showing significant inflammation. Immunostaining for iNOS or NT was negative in animals given dexamethasone and CI-1018 concurrently ( Figures 2D and 3D ). Immunohistochemical findings for iNOS and NT in animals given CI-1018 with or without dexamethasone are summarized in Table 3 .
Neutrophil Depletion: Effects of rabbit anti-rat PMN antiserum on CI-1018-induced changes in circulating neutrophils are shown in Table 5 . Significant increases in neutrophil counts were evident in rats given CI-1018 alone (group 7) at 48 and 72 hours when compared to primary control group. As anticipated, average neutrophil counts were significantly decreased throughout the experiment in rats given APS and CI-1018 concurrently (group 8) relative to rats given CI-1018 alone (group 7).
Localization of Apoptosis:
In control rats, there was no labeling by TUNEL assay or by caspase-3 immunostaining (Figures 4A and 5A ). Intense TUNEL labeling of nuclei and the presence of caspase-3 immunoreactivity were indicative of apoptosis and found in medial smooth muscle cells of mesenteric arteries from CI-1018-treated rats ( Figures 4B,  C and 5B). Nuclear fragmentation and caspase-3 immunostaining was a predominant feature of smooth muscle cells only, and only in arteries with medial hemorrhage, necrosis and mixed inflammatory cell infiltration (Table 3 ). The endothelium, however, did not stain for either caspase-3 or TUNEL. In contrast to rats given CI-1018 alone, and similar to control groups, sections of mesenteric vessels from animals treated with dexamethasone and CI-1018 were negative for TUNEL ( Figure 4D ) and caspase-3 ( Figure 5C ). Although histopathological evaluation on mesenteric vessels from rats given CI-1018 and APS concurrently (group 8) demonstrated that neutrophil depletion diminished the incidence and histologic severity of vasculitis, caspase-3 immunoreactivity in vascular smooth muscle cells remained ( Figure 5D) .
Colocalization of Caspase-3 with iNOS, NT or Smooth Muscle Actin: Dual immunohistochemical labeling for the cleaved form of caspase-3 with iNOS, NT or smooth muscle actin was performed on histological sections from CI-1018-treated animals. Caspase-3 positive vascular smooth muscle cells were typically found in close proximity to infiltrated inflammatory cells in the media and accompanied by intense iNOS or NT immunostaining ( Figure 6A, B) . Dual staining for caspase-3 with smooth muscle actin confirmed that caspase-3 immunostaining was confined to medial smooth muscle cells ( Figure 6C ).
DISCUSSION
An increased incidence of TUNEL-positive and caspase-3 immunoreactive medial smooth muscle cells in mesenteric arteries suggests that apoptosis of these cells is a prominent histopathological feature of vasculitis induced by CI-1018 in rats. Similar findings were shown in in vitro studies using several cell types, including human aortic vascular smooth muscle cells, exposed to PDE III inhibitor cilostazol (14) , PDE I inhibitor (vinpocetine) (16) or PDE IV inhibitor (Rolipram) (23) . In contrast to the present study, in which apoptosis was limited to smooth muscle cells, Zhang et al. (37) have reported both endothelial cell and smooth muscle cell apoptosis in mesenteric arteries of rats given a single intraperitoneal dose of the PDE III inhibitor SK&F 95654. Differences in susceptibility of endothelial cells to apoptosis following exposure to SKF 95654 or CI-1018 is not known, but could conceivably be related to differential expression of PDE III and PDE IV subtypes within the endothelium. In the present study, medial smooth muscle cell apoptosis was observed only in mesenteric arteries from rats administered CI-1018 alone and only in vessels exhibiting significant inflammatory cell infiltrates. In addition, dexamethasone mitigated inflammatory cell infiltration induced by CI-1018 and eliminated the numbers of TUNEL-positive and caspase-3 immunoreactive smooth muscle cells. In a separate study where female Wistar rats received daily oral doses of CI-1018 at 750 mg/kg and euthanized at 2, 4, 6, 8, 16, 24, 48 and 72 hours, mixed inflammatory cell infiltrates were observed in mesenteric vessels as early as 16 hours. TUNEL positive and caspase-3 immunostaining was observed only at 48 and 72 hours (data not shown). Our data suggest that apoptosis may be an event secondary to mesenteric inflammation, rather than a direct consequence of PDE IV inhibition.
Consistent with the apparent link between smooth muscle cell apoptosis and the inflammatory response observed in the present study, the cytotoxic inflammatory mediators nitric oxide (NO . ) and peroxynitrite (ONOO − ) have been shown to trigger apoptosis in a number of cell types in vitro, including rat and rabbit aortic smooth muscle cells, macrophages, and pancreatic acinar cells (6, 24, 29, 33) . Increased iNOS expression and nitrotyrosine immunoreactivity in the present study also support a role for nitrative stress in CI-1018-induced vasculitis. Although not investigated directly in the context of PDE inhibitor-related vasculitis, nitric oxide-induced apoptosis appears to be mediated by several effectors, including c-Jun amino terminal kinase/stress activated protein kinase (JNK/SAPK) (28), caspases (35), the Bcl-2 family of proteins (3), and cytochrome c (9) .
Unlike inflammatory foci that showed nitrotyrosine immunostaining, iNOS-positive endothelial cells were not immunoreactive for nitrotyrosine suggesting that under the conditions of this study, NO
. was not present at a level sufficient to cause detectable protein nitration. Likewise, NO
. may be easily eliminated from endothelial cells by interactions with oxyhemoglobin in the close proximity bloodstream. On the other hand, NO
. production and ONOO − formation by inflammatory cell infiltrates may provide the putative link between medial smooth muscle cell apoptosis and the inflammatory response observed in this study. This is further supported by the lack of immunostaining for iNOS and nitrotyrosine in rats given dexamethasone concurrently with CI-1018. Dexamethasone has been shown in a number of cell types, including hepatocytes and macrophages, to transcriptionally block iNOS gene expression and NO
. production (10, 11, 13) . As well, glucocorticoids have been shown to inhibit selectively induction of iNOS in vascular endothelial cells (30) . It is conceivable that control of iNOS expression by dexamethasone could partly account for the absence of apoptosis in medial smooth muscle cells of rats given dexamethasone concurrently with CI-1018. In contrast however, caspase-3 immunostaining in medial smooth muscle cells remained in rats given APS concurrently with CI-1018 despite a significant decrease in average neutrophil counts throughout the experiment. The presence of caspase-3 immunoreactivity in individual rats with negligible circulating neutrophils is suggestive that medial smooth muscle cell apoptotic signaling is not mediated solely by neutrophil activation triggered by CI-1018 administration, but may also indicate a role of other inflammatory cells in this signaling process.
A role for nitrative stress in initiating smooth muscle cell apoptosis was supported in the dual immunohistochemistry studies by co-localization in the media of inflammatory cells exhibiting iNOS and nitrotyrosine immunoreactivity with smooth muscle cells containing caspase-3 immunoreactivity. Although iNOS was expressed in both EC and medial inflammatory cell infiltrates, only smooth muscle cells were susceptible to apoptosis, which may be consistent with NO . acting as either proapoptotic or survival promoting factor depending upon cell types, or alternatively, on experimental design (2, 5, 6, 8, 19, 22, 36) .
In summary, increased expression of iNOS and nitrotyrosine immunoreactivity in vasculitic mesenteric arteries and co-localization of inflammatory cells expressing increased levels of iNOS and nitrotyrosine immunoreactivity with mesenteric smooth muscle cells exhibiting significant caspase-3 immunostaining indicates that nitrative stress plays an important contributing role in mesenteric vasculitis induced in rats by the phosphodiesterase type IV inhibitor CI-1018. Confinement of medial smooth muscle cell apoptosis to areas with active inflammation in CI-1018-treated group and its inhibition by dexamethasone may suggest that smooth muscle cell apoptosis is secondary to the inflammatory response rather than an event related to PDE IV inhibition. The failure of antineutrophil antiserum to block caspase-3 activation, however, suggests that apoptosis of smooth muscle cells to be independent of neutrophil activation.
